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Abstract
In castration-resistant prostate cancer (CRPC), several life-prolonging drugs have been registered, but patient-
reported outcomes in daily practice are scare. In our study, 151 patients with CRPC completed quality of life
(QoL) questionnaires. Although the majority received life-prolonging drugs, QoL deteriorated during the course
of CRPC. Supportive care should be timely thought of to maintain QoL as long as possible.
Background: The purpose of this study was to determine generic, cancer-specific, and prostate cancer-specific
health-related quality of life (HRQoL), pain and changes over time in patients with metastatic castration-resistant
prostate cancer (mCRPC) in daily practice. Patients and Methods: PRO-CAPRI is an observational, prospective
study in 10 hospitals in the Netherlands. Patients with mCRPC completed the EQ-5D, European Organization for the
Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), and Brief Pain Inventory-Short
Form (BPI-SF) every 3 months and European Organization for the Research and Treatment of Cancer Quality of
Life Questionnaire-Prostate Cancer Module (EORTC QLQ-PR25) every 6 months for a maximum of 2 years. Sub-
groups were identified based on chemotherapy pretreatment. Outcomes were generic, cancer-specific, and prostate
cancer-specific HRQoL and self-reported pain. Descriptive statistics were performed including changes over time and
minimal important differences (MID) between subgroups. Results: In total, 151 included patients answered 873
questionnaires. The median follow-up from the start of the study was 19.5 months, and 84% were treated with at least
1 life-prolonging agent. Overall, patients were in good clinical condition (Eatern Cooperative Oncology Group per-
formance status 0-1 in 78%) with normal baseline hemoglobin, lactate dehydrogenase, and alkaline phosphatase. AtM.C.P.K. and H.M.W. contributed equally to this article.
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Real-world Quality of Life in Castration-resistant Prostate Cancerinclusion, generic HRQoL was high with a mean EQ visual analog score of 73.2 out of 100. The lowest scores were
reported on role and physical functioning (mean scores of 69 and 76 of 100, respectively), and fatigue, pain, and
insomnia were the most impaired domains. These domains deteriorated in > 50% of patients. Conclusion: Although
most patients were treated with new treatments during follow-up, mCRPC has a negative impact on HRQoL with
deterioration in all domains over time, especially role and physical functioning. These domains need specific attention
during follow-up to maintain HRQoL as long as possible by timely start of adequate supportive care management.
Clinical Genitourinary Cancer, Vol. -, No. -, --- ª 2019 Elsevier Inc. All rights reserved.
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The survival of patients with metastatic castration resistant prostate
cancer (mCRPC), that is progression of disease on androgen depri-
vation therapy, is not likely to extend beyond 14 months with only
best supportive care.1 Several life-prolonging drugs (LPDs), such as
chemotherapy (ie, docetaxel, cabazitaxel), androgen-receptor targeting
treatments (ie, abiraterone, enzalutamide), and radionuclide therapy
(ie, radium-223), have shown a survival benefit compared with pla-
cebo.2-8 In a contemporary cohort with access to these new LPDs, we
observed a median overall survival of 26 months.9
mCRPC has a negative impact on health-related quality of life
(HRQoL) with a decline in HRQoL over time.1,10-17 Deterioration
occurs in general domains as well as specific symptoms such as pain,
fatigue, and appetite loss.12 However, these results are derived from trials
performed in the era before the registration of new LPDs.1,12,15,16 In the
pivotal phase III trials, theLPDs showed a delay inHRQoLdeterioration
and pain progression in both chemotherapy-naive (CTx-naive) and post-
chemotherapy (post-CTx) disease phases,18-21 but adverse events of new
agents can also add to the symptom burden in mCRPC.
There remains a paucity of data concerning treatment sequencing
and direct comparisons of LPDs in randomized trials. Moreover,
cumulating evidence on real-world data points toward the fact that
trials utilize highly selected populations with significantly better
outcomes that are commonly not generalizable to an oncology
practice.9 Benefits of LPDs in trials are comparable and economic
costs are in the same range, making patient-reported outcomes
(PROs) of special interest in order to determine the best treatment.
The use of PROs in daily practice can also inform physicians on
efficacy and tolerability, increase patient satisfaction, and improve
symptom control and supportive care measures.22
The high proportion of patients experiencing HRQoL deterio-
ration owing to either disease- or treatment-related symptoms, the
lack of discriminative results from trials, and the gap between these
trials and real-world practice underline the necessity for PROs in
daily practice. The objective of this study is therefore to determine
generic, cancer-specific, and prostate cancer-specific HRQoL and
changes over time in patients with mCRPC using data from a pa-
tient registry in the Netherlands.
Patients and Methods
Study Design and Setting
PRO-CAPRI is a prospective observational cohort study in 10
hospitals in the Netherlands. The study aimed to evaluate HRQoL,nical Genitourinary Cancer Month 2019pain, and resource use outside the hospital in daily practice using
validated questionnaires. The study was approved by a central and
local medical ethics committee and hospital board before the start of
inclusion. The PRO-CAPRI study is registered in the Dutch Trial
Registry as NL3934 (NTR4096). PRO-CAPRI is a side study of the
CAstration-resistant Prostate cancer RegIstry (CAPRI) registered as
NL3440 (NTR3591). The methods of the CAPRI registry have
been described in depth previously.9
Objectives
The objectives are to determine generic, cancer-specific, and
prostate cancer-specific HRQoL, pain, and changes over time in
patients with mCRPC in daily practice.
Participants
Patients diagnosed with mCRPC between January 1, 2010 and
December 31, 2015 were eligible for inclusion, conforming to the
CAPRI inclusion criteria.9 Patients were eligible for the PRO-
CAPRI study from diagnosis of CRPC to 4 weeks after the start
of the first post-docetaxel treatment. Eligible patients provided
written informed consent to the treating physician at the hospital
site. All PRO-CAPRI patients were also included in the CAPRI
registry.
Subgroups were created based on the disease state at inclusion,
namely chemotherapy-naive state (CTx-naive [ie, no prior docetaxel
treatment]) and (post-) chemotherapy state (post-CTx [ie, current
docetaxel or post-docetaxel treatment]).
Study Size
In PRO-CAPRI, 167 participants were included out of the total
of 3616 patients with mCRPC that were included in the CAPRI
registry.
Follow-up and Data Collection
PRO-CAPRI started in June 2013 with 4 participating hospitals,
but because of slow accrual, the protocol was amended after 1 year
to include an additional 6 hospitals and prolong the inclusion
period for 6 months. This amendment also included the addition of
the pain-specific questionnaire, the Brief Pain Inventory-Short
Form (BPI-SF).
The baseline evaluation of consenting patients consisted of 4
questionnaires (EQ-5D, European Organization for the Research
and Treatment of Cancer Quality of Life Questionnaire [EORTC
Malou C.P. Kuppen et alQLQ-C30], European Organization for the Research and Treat-
ment of Cancer Quality of Life Questionnaire-Prostate Cancer
Module [EORTC QLQ-PR25], and after the amendment, BPI-SF)
and commonly used demographic items, namely age, socio-
economic status, marital status, and educational level. After base-
line measurement, EQ-5D, EORTC QLQ-C30, and BPI-SF were
repeated every 3 months, and EORTC QLQ-PR25 every 6 months.
All patients were followed until death, withdrawal of consent, or end
of study duration (either a total follow-up period of 2 years from the
start of the study or December 31, 2017).
A case record form linked the participating patient to the CAPRI
database, combining HRQoL with the clinical characteristics.
Outcome
The primary outcome was generic HRQoL, measured with EQ-
5D. The first part of the EQ-5D is a generic 5-dimensional ques-
tionnaire on a 5-point Likert scale, which was transformed into
utility or EQ-5D index value based on Dutch population norms.23
The second part is a visual analogue scale (VAS).24
The secondary outcomes were cancer-specific HRQoL, prostate
cancer-specific HRQoL, and pain. The EORTC QLQ-C30 (can-
cer-specific HRQoL) and EORTC QLQ-PR25 (prostate cancer-
specific HRQoL) include 55 questions in different HRQoL do-
mains, including functional scales, symptom scales, and a global
health status. For the majority of items, a 4-point Likert-type
response scale was used. Exception is the global health status,
where a 7-point scale was used. All EORTC QLQ-C30 and
EORTC QLQ-PR25 scales were linearly transformed to a scale
from 0 to 100 according to the scoring manual.25,26 The BPI-SF
assesses severity of pain (4 items), impact of pain on daily func-
tion (7 items), location of pain, pain medication, and amount of
pain relief in the past 24 hours or the past week. The areas were
measured on a scale from 0 to 10, with 0 indicating “no pain” and
10 indicating “worst possible pain.”27 Clinically relevant pain was
defined as a score of  4 on pain severity. Supplemental Table 1 (in
the online version) shows an overview of the used questionnaires.
Both the primary and secondary outcomes are measured at
baseline (ie, inclusion) and over time. A minimally important dif-
ference (MID) was used to assess clinically relevant changes.27-30
The thresholds for MIDs are also shown in Supplemental Table 1
(in the online version). Time to first MID deterioration was
calculated in months from the date of first questionnaire to the date
of first MID deterioration.
Missing Values
Missing values were handled based on the scoring manual for the
specific questionnaires. In EQ-5D, the index value and VAS were
calculated if all domains were present.24 For EORTC QLQ-C30,
EORTC QLQ-PR25, and BPI-SF, averages were calculated if
more than one-half of the questions were completed per scale.25-27
Statistical Analysis
The compliance rate was calculated as the number of patients
returning a questionnaire divided by the total number of evaluable
patients per questionnaire. Baseline characteristics were measured in
the period of 3 months prior to 3 months after inclusion.
Descriptive statistics were used to describe the study populationwith subgroups per disease state at inclusion. Data on HRQoL were
presented as mean changes from baseline and proportion with MID.
The McNemar test was used for differences in proportion with
MID between 6 and 12 months for subgroups. The independent
sample t test, Mann-Whitney U test, or c2 test were used to
compare parametric continuous, nonparametric continuous, and
categorical variables, respectively, between CTx-naive and post-CTx
patients. A P-value of .05 or less was considered statistically sig-
nificant. IBM SPSS Statistics Version 24.0 (IBM, Armonk, NY) was
used for all analyses.
Results
In total, 167 patients were included in the PRO-CAPRI study.
Nine patients were excluded for failing to meet the inclusion criteria
(n ¼ 7) or missing informed consent (n ¼ 2). Seven of the 158
patients who were sent the first questionnaire did not respond,
either owing to death (n ¼ 4), withdrawal of consent (n ¼ 2), or
inability to answer (n ¼ 1). Baseline questionnaires were evaluable
for 151 patients (Figure 1).
In total, 873 questionnaires were completed, and the median
number of questionnaires per patient was 6 (range, 1-9). The me-
dian follow-up from the first questionnaire was 19.5 months (IQR,
13-25 months). Thirty-eight (25%) patients completed all 9 ques-
tionnaires. Termination of the study before the maximum follow-up
of 2 years occurred in 113 (75%) patients, owing to death (n ¼ 56;
37%), lost-to-follow-up (n ¼ 22; 15%), withdrawal of informed
consent (n ¼ 9; 6%), or database cutoff (n ¼ 26; 17%). The
compliance rate ranged from 94% to 100% per questionnaire,
except for BPI-SF, which was added during the study after a pro-
tocol amendment (see Supplemental Table 2 in the online version).
Treatment Characteristics
At inclusion, 112 (74%) patients were in the CTx-naive state,
and 39 (26%) patients were in the post-CTx state. At the time of
the first questionnaire, 37 (33%) patients in the CTx-naive state
were treated with LPD, mainly enzalutamide (n ¼ 27; 24%),
whereas in the post-CTx state, most patients were treated with
docetaxel (n ¼ 17; 44%). During follow-up, 84% of patients were
treated with at least 1 LPD, mainly enzalutamide (n ¼ 89; 59%) or
docetaxel (n ¼ 65; 43%) (Table 1).
Patient and Disease Characteristics
At mCRPC diagnosis, patients included in the PRO-CAPRI
study were younger (72 vs. 75 years; P < .01) and had higher
hemoglobin (8.3 vs. 8.0 mmol/L; P ¼ .01) compared with the total
mCRPC population in the CAPRI registry (see Supplemental
Table 3 in the online version).
CTx-naive patients were older (median 75 vs. 71 years; P ¼ .02),
had less prevalent bone metastases (73% vs. 82%; P ¼ .03), and had
lower educational level (P ¼ .03) at inclusion than post-CTx pa-
tients (Table 1). PSA tended to be lower in CTx-naive patients
(median, 36 vs. 86 mg/L; P ¼ .06).
Generic HRQoL (EQ-5D)
Generic HRQoL was high, with a mean EQ VAS of 73.2 of 100
and EQ-5D index value of 0.82 of 1 at inclusion. Most problems
were reported on pain/discomfort (55%) and mobility (48%). NoClinical Genitourinary Cancer Month 2019 - 3
Figure 1 Flowchart of Patient Inclusion
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(Figure 2A, Supplemental Table 4 [in the online version]).
EQ VAS deteriorated over time, but changes were small, and the
mean change did not reach MID during 24 months of follow-up
(Figure 3A). There were no differences in proportion with MID
deterioration at 6 and 12 months (Table 2, Supplemental Table 5
[in the online version]). The median time to MID deterioration
on generic HRQoL was 10.8 months for EQ VAS, without dif-
ferences between CTx-naive and post-CTx patients (Table 3,
Supplemental Table 6 [in the online version]).
Cancer-specific HRQoL (EORTC QLQ-C30)
Figure 2A and B show cancer-specific HRQoL at inclusion. Role
(ie, patient's ability to perform daily activities, leisure time activities,nical Genitourinary Cancer Month 2019and/or work) and physical functioning were most affected in cancer-
specific HRQoL (mean scores of 69 and 76 of 100, respectively).
CTx-naive patients had significant but not relevant lower levels of
emotional functioning compared with post-CTx patients (mean
scores of 81 vs. 88; P ¼ .02). Most symptoms were measured on
scales of fatigue, pain, and insomnia, without differences in sub-
groups per disease state (Figure 2A and B).
Deterioration was seen on all functioning domains of EORTC
QLQ-C30, except for emotional functioning (Figures 3B-G). The
proportion of CTx-naive patients with MID after 12 months was
higher compared with after 6 months in global health status (32% vs.
18%; P ¼ .03), physical functioning (44% vs. 27%; P ¼ .02), role
functioning (45% vs. 27%; P¼ .02), and social functioning (35% vs.
19%; P ¼ .01). In post-CTx patients, no differences in proportion
Table 1 Patient and Disease Characteristics per Disease State
Total N [ 151 CTx-naive N [ 112 Post-CTx N [ 39 P Value
Age, y .020
Median (IQR) 74 (68-80) 75 (68-81) 71 (68-75)
Range 54-95 54-95 58-84
ECOG performance status, % .235
0 38 39 36
1 40 35 54
>1 9 10 5
Unknown 13 16 5
Gleason score, % .431
7 34 35 31
8-10 56 53 64
No histology 3 5 0
Metastasis biopsy 1 1 3
Unknown 6 7 3
Charlson comorbidity index, % .565
6 69 66 77
7-8 25 27 21
9-10 5 6 3
>10 1 1 0
Unknown 0 0 0
Disease state, %
N1/N0/Nx 49/13/38 44/13/44 64/15/21 .749
M1/M0/Mx (bone) 76/8/17 73/5/22 82/18/0 .031
M1/M0/Mx (visceral) 9/31/60 5/25/70 18/49/33 .387
Period from castration to
mCRPC, mos
.105
Median (IQR) 15.1 (9-28) 16.5 (9-32) 13.0 (7-22)
Unknown, % 0 0 0
Period from mCRPC to inclusion
PRO-CAPRI, mos
<.001
Median (IQR) 7.0 (2.0-21.0) 4.7 (1-14) 19.4 (10-29)
Unknown, % 0 0 0
Hemoglobin, mmol/L .479
Median (IQR) 8.0 (7.3-8.5) 8.1 (7.5-8.5) 8.0 (7.1-8.4)
Unknown, % 2.6 3 3
Lactate dehydrogenase, U/L .341
Median (IQR) 213 (185-261) 211 (182-259) 218 (187-281)
Unknown, % 7 7 5
Alkaline phosphatase, U/L .421
Median (IQR) 103 (72-173) 102 (72-168) 113 (76-254)
Unknown, % 2 3 0
Prostate-specific antigen, mg/L .061
Median (IQR) 40.4 (12-121) 36.0 (11-106) 86.0 (14-180)
Unknown, % 2 3 0
Marital state, % .210
Married/living together 85 83 90
Single/not living together 5 4 8
Divorced 3 4 0
Widowed 8 10 3
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Table 1 Continued
Total N [ 151 CTx-naive N [ 112 Post-CTx N [ 39 P Value
Educational level, %a .030
None 1 1 0
Low 39 45 23
Middle 15 11 26
High 38 35 46
Other/unknown 8 9 5
Current profession, % .395
Employed 8 7 10
Entrepreneur 7 10 0
Incapacitated 3 2 5
Retired/early retired 79 78 82
Other/unknown 3 4 3
Treatment at inclusion, %b
None 24 32 0 <.001
No LPD 26 35 0 <.001
LPD 50 33 100 <.001
Docetaxel 11 0 44 <.001
Cabazitaxel 1 0 3 .089
Abiraterone acetate 12 9 18 .125
Enzalutamide 27 24 36 .001
Radium-223 0 0 0 e
Study drug 0 0 0 e
Treatment during follow-up, %c
None 6 9 0 .053
No LPD 15 18 8 .128
LPD 84 80 97 .008
Docetaxel 43 44 41 .767
Cabazitaxel 19 14 31 .023
Abiraterone acetate 25 23 28 .533
Enzalutamide 59 59 59 .996
Radium-223 11 11 10 .936
Study drug 3 4 3 .762
All baselines measured are measured within 3 months prior or after the start of study. Percentages may exceed 100% owing to rounding.
P values calculated for differences in time to first minimally important difference between CTx-naive and post-CTx patients.
Abbreviations: ADT ¼ androgen deprivation therapy; CTx-naive ¼ no or no prior docetaxel chemotherapy at inclusion; ECOG ¼ Eastern Cooperative Oncology Group; IQR ¼ interquartile range; LPD ¼
life prolonging drug (either docetaxel, cabazitaxel, abiraterone, enzalutamide or radium-223); mCRPC ¼ metastastic castration-resistant prostate cancer; post-CTx ¼ current or post-docetaxel
chemotherapy at inclusion.
aEducational level converted to classes according to the Dutch Central Bureau of Statistics (CBS).31
bAny systemic treatment at time of first questionnaire.
cAny systemic treatment at time of second or later questionnaires.
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6 - Cliwith MID deterioration after 6 and 12 months was seen. Symptoms
increased over time, with the highest proportion of patients withMID
in fatigue and appetite loss. The proportion of patients withMIDafter
12months was higher than after 6months for pain (22%vs. 36%;P<
.01), which was only present in the CTx-naive subgroup (see
Supplemental Table 5 in the online version).
All functioning domains of EORTC QLQ-C30 deteriorated
approximately 1 year after inclusion, except for emotional functioning
(median, 26.6 months) (Table 3). The median time to deterioration of
the symptoms fatigue and pain were, respectively, 8.2 and 15.3 months.nical Genitourinary Cancer Month 2019Prostate Cancer-specific HRQoL (EORTC QLQ-PR25)
At inclusion, 31 (21%) patients reported any sexual activity
measured with EORTC QLQ-PR25, with higher activity levels in
CTx-naive patients than in post-CTx patients (mean, 8.5 vs. 1.4;
P ¼ .02). Prostate cancer-specific symptoms were mostly present as
urinary symptoms at inclusion. CTx-naive patients reported more
bowel symptoms than post-CTx patients (mean 8.9 vs. 3.7; P ¼
.04). During follow-up, sexual activity and prostate cancer-specific
symptoms remained stable, and no clinically relevant deterioration
was observed.
Figure 2 Health-related Quality of LifeMeasured at Study Inclusion. A, Mean Scores of Functioning Scales. High Scores Indicate High Level of
Functioning. B, Mean Scores of Symptom Scales. High Scores Indicate High Symptom Burden. C, Mean Scores of Pain. High Scores
Indicate High Pain Severity or Interference. Error Bars Represent 95% Confidence Intervals. *Significant Differences at Level P < .05
Abbreviations: BPI-SF ¼ Brief Pain Inventory-Short Form; CTx-naive ¼ no or no prior docetaxel chemotherapy at inclusion; post-CTx ¼ current or post-docetaxel chemotherapy at inclusion; EORTC
QLQ-C30 ¼ European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire; EORTC QLQ-PR25 ¼ European Organization for the Research and Treatment of Cancer
Quality of Life Questionnaire-Prostate Cancer Module; VAS ¼ visual analog scale.
Malou C.P. Kuppen et al
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The mean pain severity and interference were low at inclusion,
without differences between subgroups (Figure 2C). Sixteen percent
(17 of 108 patients with baseline BPI-SF) reported clinically rele-
vant pain at inclusion.
Thirty-six percent of patients without clinical meaningful pain at
inclusion had MID deterioration during follow-up. Eight (47.1%)
of 17 patients with clinical meaningful pain at inclusion had
evaluable follow-up questionnaires, with 4 (23.5%) reporting MID
improvement of pain. In CTx-naive patients, the proportion of
patients with MID after 12 months was higher for “worst” (29% vs.
18%; P ¼ .04) and “average” (24% vs. 13%; P ¼ .02) pain and
pain interference on daily functioning (26% vs. 11%; P < .01) than
after 6 months (see Supplemental Table 5a in the online version).
No differences between CTx-naive and post-CTx patients were
found in time to deterioration except for “worst” pain (see
Supplemental Table 6 in the online version). CTx-naive patients
had a significantly longer time to deterioration on “worst” pain than
post-CTx patients (24.5 vs. 9.9 months, respectively; P ¼ .04).
Discussion
To our knowledge, this is the largest contemporary real-world
longitudinal analysis of HRQoL during mCRPC. Previous
research mainly focused on patients treated in randomized
controlled trials, but results from these trials cannot be easily
generalized to the real-world practice.9 The absence of complicated
inclusion and exclusion criteria in our study warrants the reflection
of a real-world population in current daily practice.
In this study, we showed that at inclusion, baseline HRQoL was
relatively high. Most of our patients were in an early disease phase,
with 75% of patients without docetaxel pretreatment and a short
interval from diagnosis of castrate-resistance to inclusion into the
study. Previously published mCRPC cohorts reported lower
HRQoL.12,32 For example, the mean EQ-5D index value was 0.82
in our study, compared with 0.64 to 0.74 in other reports.12,32
However, differences between our study and previous reports can
be explained by differences in patient selection, the availability of
life-prolonging therapeutic options, and international valuation of
HRQoL measurement.33,34 This contemporary cohort indicates
that in Dutch daily practice, generic HRQoL is high in the early
mCRPC state.12,14,15,32 Most baseline symptoms were identified in
role (ie, patient’s ability to perform daily activities, leisure time
activities, and/or work) and physical functioning, with high symp-
tom burden on pain, fatigue, and insomnia.
Deterioration was seen in almost all domains of HRQoL.
Deterioration in HRQoL is part of the normal aging process, and
scores on cognitive, emotional, and social functioning are compa-
rable to the European population norms of the same age group (
70 years).35 However, we found low scores on role and physical
functioning at inclusion, probably showing the impact of mCRPC
on these domains.35 Role and physical functioning were also prone
to deterioration. Therefore, specific attention for these domains at
the start of new systemic treatment and during follow-up of pa-
tients with mCRPC is needed to maintain HRQoL as long as
possible.nical Genitourinary Cancer Month 2019A delay in HRQoL and pain progression has been reported in
randomized controlled trials of new LPDs.18-21 Eighty-four percent
of patients in our study were also treated with LPDs during follow-
up. Owing to small sample sizes, we were not able to calculate
differences between treated and untreated patients, and more spe-
cifically between treatments. In our total mCRPC population, the
median time to pain deterioration (“worst” pain) was 24.5 months
in CTX-naive and 9.9 months in post-CTX patients. This time to
progression on “worst” pain is in agreement with the chemotherapy-
naive COU-AA-302 treatment arm (25.8 months)36 and in the
post-chemotherapy COU-AA-301 treatment arm (7.4 months).37
Comparison with clinical trials, however, warrants caution owing
to differences in patient selection, outcome measures, and the
definition of MID compared with our real-world population.
In prostate cancer-specific HRQoL, we found low sexual activity
and mostly urinary symptoms at baseline. A population-based sur-
vey in the United Kingdom showed that sexual activity was low
among all stages of prostate cancer.38 Although younger patients
were concerned about the lack of sexual activity, less than one-half
of the patients were offered treatment to improve sexual health.38
The baseline assessment in individual patients with mCRPC can
address problems and concerns about sexual health and guide in-
dividual treatment. However, similar to other research, no trends in
prostate-cancer specific HRQoL were observed during follow-up.14
Therefore, the EORTC QLQ-PR25 seems of low additional value
when it comes to monitoring treatment effects and tolerability.
An important limitation of this study was the relatively small
sample size. Only 4 percent of all patients included in the CAPRI-
registry were included in the PRO-CAPRI study. At baseline
mCRPC diagnosis, patients in the PRO-CAPRI study tended to be
in better clinical condition than patients in the CAPRI-registry.
Therefore, results are possibly not generalizable for the total
Dutch population. The second limitation of this study was the non-
randomized study design that made it impossible to compare the
individual new treatments. Subgroups per treatment were too small
for reliable analyses of changes in HRQoL.
Conclusion
To conclude, in spite of the availability of LPDs, deterioration
was seen in almost all domains of HRQoL with the domains role
and physical functioning especially prone to deterioration. There-
fore, specific attention during follow-up is needed in order to
maintain HRQoL as long as possible by timely starting supportive
care management. Incorporating individual PRO assessment in
daily clinical practice can possibly aid physicians in treatment de-
cisions, monitoring treatment effects and tolerability, and
improving symptom control.
Clinical Practice Points
 Patients with mCRPC experience a decline in HRQoL over
time. Several drugs, registered for mCRPC based on a survival
benefit, also show a delay in HRQoL deterioration and pain
progression. However, there is a paucity of data on HRQoL in a
real-world population with mCRPC treated with these new
drugs.
Figure 3 Changes in HRQoL Over Time per Disease State. A, Mean Changes of EQ-VAS (Generic HRQoL). B, Mean Changes of Global
Health Status (Cancer-specific HRQoL). C, Mean Changes of Physical Functioning (Cancer-specific HRQoL). D, Mean Changes
of Role Functioning (Cancer-specific HRQoL). E, Mean Changes of Emotional Functioning (Cancer-specific HRQoL). F, Mean
Changes of Cognitive Functioning (Cancer-specific HRQoL). G, Mean Changes of Social Functioning (Cancer-specific HRQoL).
Mean Changes From Inclusion. Error Bars Represent 95% Confidence Interval and Red Line Represents MID
Abbreviations: CTx-naive ¼ No or no prior docetaxel chemotherapy at inclusion; post-CTx ¼ current or post-docetaxel chemotherapy at inclusion; HRQoL ¼ health-related quality of life; MID ¼
minimally important difference; VAS ¼ visual analog scale.
Malou C.P. Kuppen et al
Clinical Genitourinary Cancer Month 2019 - 9
Figure 3 continued
Real-world Quality of Life in Castration-resistant Prostate Cancer
10 - We have shown that patients experienced most problems in role
(ie, patient’s ability to perform daily activities, leisure time, and/
or work) and physical functioning with pain, fatigue, and
insomnia. Although 80% of our real-world population wasClinical Genitourinary Cancer Month 2019treated with new drugs, HRQoL deteriorated over time, mainly
on role and physical functioning.
 These results show the changes in HRQoL during mCRPC and
highlight specific domains prone to deterioration. The start of
Figure 3 continued
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Table 2 Proportion of Patients With a Clinically Relevant Deterioration in HRQoL at Month 6 and Month 12
Month 6 Month 12 P Value
Generic HRQoL (EQ-5D) EQ VAS 31/115 (27.0) 31/95 (32.6) .281
Cancer-specific HRQoL (EORTC
QLQ-C30)
Global health status 27/120 (22.5) 32/96 (33.3) .023
Physical functioning 38/115 (33.0) 37/90 (41.1) .170
Role functioning 36/117 (30.8) 43/93 (46.2) .009
Emotional functioning 15/119 (12.6) 19/95 (20.0) .092
Cognitive functioning 37/119 (31.1) 33/95 (34.7) .664
Social functioning 28/119 (23.5) 33/95 (34.7) .015
Fatigue 53/116 (45.7) 50/94 (53.2) .064
Nausea/vomiting 15/119 (12.6) 19/95 (20.0) .359
Pain 26/119 (21.8) 34/95 (35.8) .002
Dyspnea 26/116 (22.4) 16/93 (17.2) .267
Insomnia 16/116 (13.8) 20/94 (21.3) .118
Appetite loss 24/118 (20.3) 26/93 (28.0) .286
Constipation 17/118 (14.4) 17/94 (18.1) .664
Diarrhea 20/117 (17.1) 24/95 (25.3) .152
Financial difficulties 8/118 (6.8) 6/95 (6.3) .688
Prostate cancer-specific HRQoL
(EORTC QLQ-PR25)
Sexual activity 14/117 (12.0) 16/93 (17.2) .180
Urinary symptoms 21/115 (18.3) 22/94 (23.4) .332
Bowel symptoms 11/93 (11.8) 10/71 (14.1) .508
Hormonal therapy related
symptoms
19/118 (16.1) 24/94 (25.5) .052
Pain (BPI-SF) Pain severity 9/75 (12.0) 13/65 (20.0) .039
Worst pain 15/76 (19.7) 21/65 (32.3) .003
Average pain 10/74 (13.5) 18/63 (28.6) <.001
Least pain 9/73 (12.3) 14/64 (21.9) .118
Current pain 9/75 (12.0) 9/63 (14.3) .289
Pain 7/61 (11.5) 14/51 (27.5) .004
Data are presented as n/N (%) for total population (N ¼ 151).
P values calculated for differences percentage of patients with MID at month 6 and month 12.
Abbreviations: BPI-SF ¼ Brief Pain Inventory-Short Form; CTx-naive ¼ no or no prior docetaxel chemotherapy at inclusion; EORTC QLQ-C30 ¼ European Organization for the Research and Treatment
of Cancer Quality of Life Questionnaire; EORTC QLQ-PR25 ¼ European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Prostate Cancer Module; HRQOL ¼
health-related quality of life; MID ¼ minimal important difference; post-CTx ¼ current or post-docetaxel chemotherapy at inclusion; VAS ¼ visual analog scale.
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12 -best supportive care targeting these specific domains should be
thought of in order to maintain HRQoL as long as possible.Acknowledgments
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Malou C.P. Kuppen et alSupplemental DataSupplemental Table 1 Overview of Used Questionnaires and MID
No. Items No. Items Neededa Scale MID
EQ-5D28,29 e e e
EQ VAS 1 1 0-100 7-11
EQ-5D index value 5 5 0.594 to 1 e
EORTC QLQ-C3029,30
Physical functioningb 5 3 0-100 10
Role functioningb 2 1 0-100 10
Emotional functioningb 4 2 0-100 10
Cognitive functioningb 2 1 0-100 10
Social functioningb 2 1 0-100 10
Fatiguec 3 2 0-100 10
Nausea/vomitingc 2 1 0-100 10
Painc 2 1 0-100 10
Dyspneac 1 1 0-100 10
Insomniac 1 1 0-100 10
Appetite lossc 1 1 0-100 10
Constipationc 1 1 0-100 10
Diarrheac 1 1 0-100 10
Financial difficultiesc 1 1 0-100 10
EORTC QLQ-PR2529
Sexual activityb 2 1 0-100 10
Sexual functioningb 4 2 0-100 10
Urinary symptomsc 8 4 0-100 10
Bowel symptomsc 4 2 0-100 10
Hormonal therapy-related
symptomsc
6 3 0-100 10
Use of incontinence aidc 1 1 0-100 10
BPI-SF27,29
Pain severity 4 4 0-10 30% and  2 points from
baseline
Worst pain 1 1 0-10 30% and  2 points from
baseline
Least pain 1 1 0-10 30% and  2 points from
baseline
Average pain 1 1 0-10 30% and  2 points from
baseline
Current pain 1 1 0-10 30% and  2 points from
baseline
Pain interference 7 4 0-10 50% of baseline standard
deviation and 2 points
Abbreviations: BPI-SF ¼ Brief Pain Inventory-Short Form; EORTC QLQ-C30 ¼ European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire; EORTC QLQ-PR25 ¼
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Prostate Cancer Module; MID ¼ minimally important difference; VAS ¼ visual analog scale.
aThe number of items per domain needed to be completed to adequately calculate the score per domain.
bFunctional scales (high scores indicate high level of functioning).
cSymptom scales (high scores indicate high symptom burden).
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Supplemental Table 2 Compliance Rate With HRQoL Questionnaires
Months After
Inclusion Total EQ-5D EORTC QLQ-C30 EORTC QLQ-PR25 BPI-SFa
0 151 150 (99) 146 (97) 145 (96) 111 (74)
3 136 133 (98) 134 (99) e 107 (79)
6 124 122 (98) 123 (99) 120 (97) 99 (80)
9 119 118 (99) 118 (99) e 103 (87)
12 101 98 (97) 98 (97) 96 (95) 85 (84)
15 83 81 (98) 82 (99) e 71 (86)
18 70 70 (100) 70 (100) 66 (94) 57 (81)
21 55 55 (100) 55 (100) e 50 (91)
24 39 39 (100) 39 (100) 38 (97) 34 (87)
Compliance rate ¼ the number of patients completing at least one question divided by the total number of available patients per time point (ie, alive and still on study).
All data are presented as n (%).
Abbreviations: BPI-SF ¼ Brief Pain Inventory-Short Form; EORTC QLQ-C30 ¼ European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire; EORTC QLQ-PR25 ¼
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Prostate Cancer Module; HRQoL ¼ health-related quality of life.
aBPI-SF was added 1 year after study start through protocol amendment: 27% of patients was enrolled before protocol amendment.
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Supplemental Table 3 Representativeness of PRO-CAPRI Population Based on Baseline Characteristics
PRO-CAPRI, N [ 151 CAPRI, N [ 3616 P Value
Age, y
Median (range) 72 (54-94) 75 (46-99) .002
75 y, % 41 52 .006





Gleason score, % .602
7 34 34
8-10 56 51
No histology 3 3
Metastasis biopsy 1 1
Unknown 6 10







N1/N0/Nx 5/46/49 7/28/65 .020
M1/M0/Mx (bone) 6/62/33 9/53/39 .144
M1/M0/Mx (visceral) 14/3/83 16/4/81 1.000
Period from castration to mCRPC, mos .986
Median (IQR) 15.1 (9-28) 15.1 (8-29)
Unknown, % 0 <1
Hemoglobin, mmol/L .014
Median (IQR) 8.3 (7.6-8.8) 8.0 (7.3-8.6)
Unknown, % 30 34
Lactate dehydrogenase, U/L .058
Median (IQR) 212 (184-249) 223 (188-294)
Unknown, % 47 59
Alkaline phosphatase, U/L .041
Median (IQR) 97 (75-150) 106 (78-192)
Unknown, % 30 37
Prostate-specific antigen, mg/L .247
Median (IQR) 15.0 (5-44) 16.7 (6-62)
Unknown, % 1 3
Treatment during follow-up, % <.001
None 1 12
No LPD 5 25
LPD 94 63
Docetaxel 66 43 <.001
Cabazitaxel 25 13 <.001
Abiraterone 38 32 .106
Enzalutamide 72 30 <.001
Radium-223 17 8 <.001
All baseline measurements were included if they were measured in the period of 3 months prior or 3 months after mCRPC diagnosis.
Tested for statistical significance between the PRO-CAPRI subgroup and the rest of CAPRI-population (N ¼ 3465).
Abbreviations: ADT¼ Androgen deprivation therapy; CTx-naive ¼ no or no prior docetaxel chemotherapy at inclusion; ECOG ¼ Eastern Cooperative Oncology Group; IQR ¼ interquartile range; LPD ¼
life prolonging drug (either docetaxel, cabazitaxel, abiraterone, enzalutamide or radium-223); mCRPC ¼ metastastic castration-resistant prostate cancer; post-CTx ¼ current or post-docetaxel
chemotherapy at inclusion.
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Supplemental Table 4 Assessment of HRQoL With Subgroups per Disease State at Inclusion
Total N [ 151 CTx-naive N [ 112 Post-CTx N [ 39 P Value
Generic HRQoL (EQ-5D) Mobility, %a 48 47 49 .775
Self-care, %a 15 16 10 .404
Usual activities, %a 43 43 44 .774
Pain/discomfort, %a 55 46 51 .698
Anxiety/depression, %a 27 28 23 .630
EQ VAS 73.2 (17) 72.9 (17) 73.9 (16) .848
EQ-5D index value 0.82 (0.17) 0.82 (0.16) 0.82 (0.16) .796
Cancer-specific HRQoL
(EORTC QLQ-C30)
Global health status 75.9 (17) 75.5 (18) 76.9 (12) .954
Physical functioning 76.1 (23) 75.8 (24) 76.8 (23) .972
Role functioning 69.3 (32) 68.8 (32) 71.0 (30) .853
Emotional functioning 82.8 (18) 80.9 (19) 88.4 (14) .022
Cognitive functioning 85.4 (18) 84.7 (18) 87.5 (17) .455
Social functioning 80.5 (27) 78.9 (29) 85.2 (21) .405
Fatigue 32.3 (25) 32.6 (26) 31.6 (21) .963
Nausea/vomiting 5.5 (15) 5.9 (17) 4.2 (10) .770
Pain 23.4 (25) 25.2 (26) 18.1 (20) .243
Dyspnea 18.9 (27) 18.2 (26) 21.3 (28) .516
Insomnia 22.8 (28) 24.3 (28) 18.5 (27) .235
Appetite loss 11.0 (25) 10.4 (24) 13.0 (27) .490
Constipation 12.8 (22) 14.8 (24) 6.5 (13) .083
Diarrhea 10.0 (23) 9.4 (23) 12.0 (23) .260




Sexual activity 6.7 (16) 8.5 (18) 1.4 (5) .016
Sexual functioningb 55.2 (22) 58.3 (18) 45.0 (33) .246
Urinary symptoms 21.1 (17) 22.7 (18) 16.4 (14) .057
Bowel symptoms 7.4 (14) 8.9 (16) 3.7 (8) .038
Incontinence aidc 13.3 (29) 14.7 (23) 9.1 (22) .407
Hormonal therapy related
symptoms
16.6 (13) 16.9 (14) 15.8 (10) .980
Pain (BPI-SF) Pain severity
Worst pain 2.22 (2) 2.21 (3) 2.24 (2) .530
Average pain 1.82 (2) 1.89 (2) 1.58 (2) .960
Least pain 1.11 (2) 1.12 (2) 1.08 (2) .858
Current pain 1.52 (2) 1.67 (2) 0.96 (1) .407
Pain interference 1.73 (2) 1.82 (2) 1.42 (2) .492
All data are presented as mean (SD) unless listed otherwise.
Percentages can exceed 100% owing to rounding.
P values calculated for differences in time to first MID between CTx-naive and post-CTx patients.
Abbreviations: BPI-SF ¼ Brief Pain Inventory-Short Form; CTx-naive ¼ no or no prior docetaxel chemotherapy at inclusion; EORTC QLQ-C30 ¼ European Organization for the Research and Treatment
of Cancer Quality of Life Questionnaire; EORTC QLQ-PR25 ¼ European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Prostate Cancer Module; HRQOL ¼
health-related quality of life; post-CTx ¼ current or post-docetaxel chemotherapy at inclusion; SD ¼ standard deviation; VAS ¼ visual analog scale.
aPercentage of patients reporting any problems (level 2 to 5).
bMean scores of patients reporting any sexual activity.
cMean scores of patients reporting any use of incontinence aid.
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Supplemental Table 5a Proportion of CTx-naive Patients With a Clinically Relevant Deterioration and Time to Deterioration in HRQoL
at Month 6 and Month 12
Month 6 Month 12 P Value
Generic HRQoL (EQ-5D) EQ VAS 22/85 (25.9) 23/73 (31.5) .556
Cancer-specific HRQoL (EORTC
QLQ-C30)
Global health status 16/90 (17.8) 24/75 (32.0) .027
Physical functioning 23/85 (27.1) 30/69 (43.5) .019
Role functioning 24/88 (27.3) 33/73 (45.2) .017
Emotional functioning 8/89 (9.0) 13/74 (17.6) .096
Cognitive functioning 27/89 (30.3) 27/74 (36.5) .302
Social functioning 17/89 (19.1) 26/74 (35.1) .007
Fatigue 38/86 (44.2) 39/73 (53.4) .096
Nausea/vomiting 12/89 (13.5) 13/74 (17.6) .791
Pain 18/89 (20.2) 25/74 (33.8) .019
Dyspnea 20/86 (23.3) 14/72 (19.4) .549
Insomnia 13/86 (15.1) 16/73 (21.9) .227
Appetite loss 19/88 (21.6) 21/72 (29.2) .302
Constipation 14/88 (15.9) 15/73 (20.5) .648
Diarrhea 15/87 (17.2) 20/74 (27.0) .238
Financial difficulties 6/88 (6.8) 6/74 (8.1) .688
Prostate cancer-specific HRQoL
(EORTC QLQ-PR25)
Sexual activity 12/86 (14.0) 16/71 (22.5) .070
Urinary symptoms 16/83 (19.3) 18/71 (25.4) .424
Bowel symptoms 10/66 (15.2) 8/52 (15.4) .688
Hormonal therapy related
symptoms
11/87 (12.6) 18/72 (25.0) .035
Pain (BPI-SF) Pain severity 6/56 (10.7) 9/52 (17.3) .219
Worst pain 10/57 (17.5) 15/52 (28.8) .039
Average pain 7/56 (12.5) 12/51 (23.5) .016
Least pain 7/54 (13.0) 11/51 (21.6) .267
Current pain 6/57 (10.5) 5/50 (10.0) 1.000
Pain interference 5/46 (10.9) 11/42 (26.2) .008
Data are presented as n/N (%) for total population (N ¼ 112).
P values calculated for differences between proportion of patients with MID at month 6 and month 12.
Abbreviations: BPI-SF ¼ Brief Pain Inventory-Short Form; CTx-naive ¼ no or no prior docetaxel chemotherapy at inclusion; EORTC QLQ-C30 ¼ European Organization for the Research and Treatment
of Cancer Quality of Life Questionnaire; EORTC QLQ-PR25 ¼ European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Prostate Cancer Module; HRQoL ¼ health-
related quality of life; MID ¼ minimal important difference; VAS ¼ visual analog scale.
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Supplemental Table 5b Proportion of Post-CTx Patients With a Clinically Relevant Deterioration and Time to Deterioration in HRQoL
at Month 6 and Month 12
Month 6 Month 12 P Value
Generic HRQoL (EQ-5D) EQ VAS 9/30 (30.0) 8/22 (36.4) .375
Cancer-specific HRQoL (EORTC
QLQ-C30)
Global health status 11/30 (36.7) 8/21 (38.1) 1.000
Physical functioning 15/30 (50.0) 7/21 (33.3) .453
Role functioning 12/29 (41.4) 10/20 (50.0) .453
Emotional functioning 7/30 (23.3) 6/21 (28.6) .688
Cognitive functioning 10/30 (33.3) 6/21 (28.6) .688
Social functioning 11/30 (36.7) 7/21 (33.3) 1.000
Fatigue 15/30 (50.0) 11/21 (52.4) .688
Nausea/vomiting 3/30 (10.0) 6/21 (28.6) .375
Pain 8/30 (26.7) 9/21 (42.9) .063
Dyspnea 6/30 (20.0) 2/21 (9.5) .500
Insomnia 3/30 (10.0) 4/21 (19.0) .625
Appetite loss 5/30 (16.7) 5/21 (23.8) 1.000
Constipation 3/30 (10.0) 2/21 (9.5) 1.000
Diarrhea 5/30 (16.7) 4/31 (19.0) .688
Financial difficulties 2/30 (6.7) 0/21 (0.0) 1.000
Prostate cancer-specific HRQoL
(EORTC QLQ-PR25)
Sexual activity 2/31 (6.5) 0/22 (0.0) 1.000
Urinary symptoms 5/32 (15.6) 4/23 (17.4) 1.000
Bowel symptoms 1/27 (3.7) 2/19 (10.5) 1.000
Hormonal therapy related
symptoms
8/31 (25.8) 6/22 (27.3) 1.000
Pain (BPI-SF) Pain severity 3/19 (15.8) 4/13 (30.8) .250
Worst pain 5/19 (26.3) 6/13 (46.2) .125
Average pain 3/18 (16.7) 6/12 (50.0) .063
Least pain 2/19 (10.5) 3/13 (23.1) .500
Current pain 3/18 (16.7) 4/13 (30.8) .250
Pain interference 2/15 (13.3) 3/9 (33.3) 1.000
Data are presented as n/N (%) for CTx-naive population (N ¼ 39).
P values calculated for differences between proportion of patients with MID at month 6 and month 12.
Abbreviations: BPI-SF ¼ Brief Pain Inventory-Short Form; EORTC QLQ-C30 ¼ European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire; EORTC QLQ-PR25 ¼
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Prostate Cancer Module; HRQoL ¼ health-related quality of life; MID ¼ minimal important difference;
post-CTx ¼ current or post-docetaxel chemotherapy at inclusion.
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Supplemental Table 6 Time to Clinical Relevant Deterioration in Months of HRQoL per Disease State
CTx-naive N [ 112 Post-CTx N [ 39 P Value
No. Events, % Time to MID, mos No. Events, % Time to MID, mos
Generic HRQoL (EQ-
5D)




Global health status 55.4 15.1 (7-26) 51.3 13.4 (7-NR) .978
Physical functioning 58.9 14.7 (6-26) 59.0 6.8 (4-NR) .490
Rolefunctioning 63.4 12.3 (5-22) 51.3 12.1 (4-NR) .521
Emotional functioning 31.3 26.6 (12-NR) 41.0 NR (6-NR) .167
Cognitive functioning 52.7 12.6 (6-28) 56.4 10.0 (6-NR) .847
Social functioning 53.6 14.2 (9-NR) 61.5 9.5 (6-NR) .276
Fatigue 64.3 8.6 (4-23) 71.8 6.5 (4-13) .381
Nausea/vomiting 44.6 19.9 (9-NR) 53.8 15.3 (9-25) .279
Pain 52.7 15.8 (6-NR) 66.7 10.2 (6-24) .200
Dyspnea 42.9 22.6 (8-NR) 43.6 20.1 (7-NR) .805
Insomnia 43.8 21.8 (9-NR) 33.3 NR (10-NR) .356
Appetite loss 50.9 16.5 (8-NR) 41.0 NR (9-NR) .459
Constipation 39.3 24.5 (9-NR) 35.9 24.1 (12-NR) .672
Diarrhea 35.7 NR (10-NR) 38.5 21.7 (8-NR) .696




Sexual activity 17.0 NR (NR-NR) 5.1 NR (NR-NR) .092
Sexual functioning 2.7 NR (NR-NR) 0 NR (NR-NR) .353
Urinary symptoms 28.6 25.6 (15-NR) 20.5 NR (19-NR) .571
Bowel symptoms 18.8 NR (25-NR) 12.8 NR (NR-NR) .783
Incontinence aid 5.4 NR (NR-NR) 5.1 NR (NR-NR) .941
Hormonal therapy
related symptoms
26.8 26.3 (16-NR) 30.8 NR (12-NR) .242
Pain (BPI-SF)a Pain severity 32.6 NR (11-NR) 40.0 NR (9-NR) .408
Worst pain 41.9 24.5 (8-NR) 64.0 9.9 (7-16) .042
Average pain 32.6 NR (11-NR) 52.0 12.5 (10-NR) .072
Least pain 39.5 NR (10-NR) 36.0 NR (11-NR) .833
Current pain 30.2 NR (11-NR) 40.0 NR (9-NR) .349
Pain interference 31.4 NR (15-NR) 32.0 NR (10-NR) .633
Data are presented as percentages for number of events (ie, number of patients with MID) and median (IQR) for time to first MID.
P values calculated for differences in time to first MID between CTx-naive and post-CTx patients.
Abbreviations: BPI-SF ¼ Brief Pain Inventory-Short Form; CTx-naive ¼ no or no prior docetaxel chemotherapy at inclusion; EORTC QLQ-C30 ¼ European Organization for the Research and Treatment
of Cancer Quality of Life Questionnaire; EORTC QLQ-PR25 ¼ European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Prostate Cancer Module; HRQoL ¼ health-
related quality of life; IQR ¼ interquartile range; MID ¼ minimal important differences; NR ¼ not reached; post-CTx¼ current or post-docetaxel chemotherapy at inclusion; VAS¼ visual analog scale.
aOnly patients with BPI-SF measurement at inclusion (CTx-naive, N ¼ 86 and post-CTx, N ¼ 25).
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